Journal of Orthopaedic Research, 21 (5), 976983
ERK1/2, VEGFR2 & Angiogenesis Signalling Review (PMC, 2025) A 2025 scoping review published in PMC evaluated BPC-157s molecular mechanisms in musculoskeletal healing
This makes it more targeted for fat loss without the broader effects on growth and IGF-1 levels
If the peptide restrictions are reversed through formal FDA rulemaking, compounding pharmacies would be legally allowed to prepare those peptides, but only as traditional, patient-specific compounded drugs, not as mass-market or FDA-approved therapies. If the peptides are formally added to the 503A bulk list, he says, pharmacies would have to follow the traditional 503A compounding rules
allow margin for priming and dropped syringes
Anyone interested in the regulatory outcome should monitor the FDA's formal rulemaking process, which must follow the advisory committee recommendation before any change takes legal effect